Grade-driven adjuvant chemotherapy benefit in high-risk stage IB NSCLC: a retrospective cohort study
ACT provides survival benefits for stage IB NSCLC patients with high-risk features, especially in poorly differentiated (G3) tumors. Histologic grading might serve as a useful tool to guide ACT decisions and to avoid potential overtreatment in moderately differentiated (G2) subgroups.
Authors
- X. Ronald Zhu (ORCID: https://orcid.org/0009-0003-4131-2916)
- Chenxu Liu (ORCID: https://orcid.org/0000-0002-0370-0294)
- Heng Tao
- Sida Lu
- Haifeng Du
- Zhuangzhuang Cong
- Jing Luo
- Haiwei Wu
- Yi Shen
Institutions
- Nanjing General Hospital of Nanjing Military Command (CN)
- Nanjing Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Journal of Thoracic Disease
- Published
- 2025-12-01
- DOI
- https://doi.org/10.21037/jtd-2025-1858
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00